The story
History
In 1870, Florenz Sartorius founded the Feinmechanische Werkstatt F. Sartorius in Göttingen at the age of 24, following the development of a short-beam analytical balance. The invention gained international recognition, and the 3,000th balance was produced in 1895. Over time, the mechanical workshop developed into a medium-sized company.
In 1906, Sartorius expanded its product portfolio through the acquisition of August Becker (Göttingen) and Ludwig Tesdorpf (Stuttgart). These companies manufactured microtomes, as well as astronomical, geodetic, and physical instruments.
In 1969, Sartorius equipment was used to test lunar samples collected during the Apollo 11 mission.
Recent history (since 2000)
In 2000, Sartorius acquired B. Braun Biotech International (BBI) from B. Braun Melsungen AG. At the time, BBI was a leading manufacturer of fermenters (bioreactors) and cell culture systems. The company was integrated into the Sartorius Group as Sartorius Stedim Systems GmbH (formerly Sartorius BBI Systems GmbH), a subsidiary of Sartorius Stedim Biotech GmbH.
Sartorius AG subsequently acquired the remaining shares in Viva Science, becoming the sole owner of the company.
In 2005, Sartorius acquired 100 percent of the shares of Omnimark Instrument Corporation, based in Arizona, United States. Omnimark manufactures moisture analyzers.
In 2007, Sartorius merged its biotechnology division with the French biotechnology company Stedim S.A. The resulting entity, Sartorius Stedim Biotech (SSB), is listed on the Paris Stock Exchange.
That same year, Sartorius acquired Toha Plast GmbH, which now operates under the name Sartorius Stedim Plastics.
Read the full text
In 2008, through its subgroup Sartorius Stedim Biotech, the company acquired Swiss-based Wave Biotech AG, a provider of single-use bioreactors.
In 2011, Sartorius acquired the liquid handling business of the Finnish laboratory equipment manufacturer Biohit. This acquisition expanded the company's portfolio of laboratory instruments.
In 2013, a new production building for injection moulding of plastic parts was opened in Göttingen. In the same year, Sartorius inaugurated its Asia sales centre in Shanghai, coordinating sales and marketing activities for China and the wider Asia region.
In 2015, Sartorius acquired the cell line and process development company Cellca. By 2017, the subsidiary Sartorius Stedim Cellca was operating from a rented facility in Laupheim. A new facility in Ulm-Eselsberg was planned and later occupied in 2019.
In 2016, Sartorius acquired two North American flow cytometry companies: IntelliCyt for US$90 million and ViroCyt for US$16 million.
In July 2017, Sartorius Stedim Biotech acquired kSep Systems, a company specialising in preparative centrifugation for recombinant proteins, vaccines, and cell therapy products.
In November 2017, Sartorius Stedim Biotech opened a new bioanalytical and biosafety testing facility in Boston.
Later in 2017, Sartorius acquired the cell-based assay and instrumentation company Essen BioScience from private equity firm SFW Capital Partners for US$320 million.
In the same period, Sartorius' Cellca subsidiary entered a co-development agreement with Synpromics to test customised synthetic promoters on Cellca's CHO expression platform, and another agreement with Nova Biomedical to develop a system for large-scale testing of diverse cell culture conditions.
In 2019, Sartorius acquired the Israeli cell culture media developer and manufacturer Biological Industries.
In 2020, the company acquired selected assets from Danaher Corporation, including products for the research and development of cell therapies.
In 2021, Sartorius acquired the German cell culture media manufacturer Xell AG, the cell and gene therapy raw materials supplier CellGenix GmbH, and the bioanalytical company ALS Automated Lab Solutions GmbH.
In 2025, Sartorius partnered with Tulip Interfaces to integrate Tulip's platform with the Sartorius Biobrain automation suite.
From Wikipedia’s article on Sartorius AG, shared under CC BY-SA 4.0.5